

Special Issue

Aged Population and Immunocompromised Patients: Impact on SARS-CoV-2 Variants and Treatment Outcomes

Message from the Guest Editors

Since the beginning of the pandemic, new “severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)” variants have emerged that can influence the airborne transmission, virulence, and immune evasion of affected individuals. The neutralizing antibodies produced as a result of vaccination or post-recovery of COVID-19 are not providing sufficient immune protection against emerging SARS-CoV-2 variants. SARS-CoV-2 variant-specific vaccines are required for better protection. A range of treatment options has become available, specifically for the aged, those with underlying health conditions, and the immunocompromised. This Special Issue seeks all types of manuscripts (e.g., reviews, research articles, and short communications) on the impact of the aged population and immunocompromised patients on SARS-CoV-2 variants, vaccine efficacy, and treatment outcomes. We cordially invite you to contribute to this Special Issue to advance our knowledge of SARS-CoV-2 and determine the means to overcome the pandemic.

Guest Editors

Prof. Dr. Vasso Apostolopoulos

Institute for Health and Sport, Victoria University, Melbourne, VIC 3011, Australia

Dr. Vivek P. Chavda

Department of Pharmaceuticals and Pharmaceutical Technology, L M College of Pharmacy, Ahmedabad 380008, Gujarat, India

Dr. Mahesh T. Chhabria

L M College of Pharmacy, Ahmedabad, Gujarat, India

Deadline for manuscript submissions

closed (31 December 2023)



Biologics

an Open Access Journal
by MDPI

CiteScore 3.7



mdpi.com/si/125244

Biologics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biologics@mdpi.com

[mdpi.com/journal/
biologics](https://mdpi.com/journal/biologics)





Biologics

an Open Access Journal
by MDPI

CiteScore 3.7



[mdpi.com/journal/
biologics](https://mdpi.com/journal/biologics)



About the Journal

Message from the Editor-in-Chief

Biologics is an international, multidisciplinary, peer-reviewed, and scientific open access, open source journal that encourages authors to submit high-quality papers in all areas of biologics derived from both novel and established biotechnologies. We invite you to contribute original research articles, review articles, perspectives or case reports for consideration and publication in the journal. Rapid turnaround time and full open access offer the opportunity to make research results immediately available to scientific communities and the general public.

Editor-in-Chief

Prof. Dr. Gary McLean

1. National Heart and Lung Institute, VPD Building, Imperial College London, London W12 0NN, UK
2. School of Human Sciences, London Metropolitan University, Holloway Road, London N7 8DB, UK

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, EBSCO, and other databases.

Journal Rank:

CiteScore - Q2 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))